← Back to Clinical Trials
Recruiting NCT06230536

NCT06230536 MARIMPACH : Contribution of High-resolution Manometry With Impedancemetry for the Evaluation of Esophageal Clearance in Achalasia

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06230536
Status Recruiting
Phase
Sponsor University Hospital, Bordeaux
Condition Esophageal Achalasia
Study Type OBSERVATIONAL
Enrollment 104 participants
Start Date 2024-02-01
Primary Completion 2028-03-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 104 participants in total. It began in 2024-02-01 with a primary completion date of 2028-03-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Outcome after treatment of achalasia is usually assessed by the Eckardt score (ES). The timed barium esophagogram (TBE) is used to objectively assess esophageal clearance after treatment. High-resolution manometry with impedancemetry (HRiM) provides information on esophageal clearance of liquids in addition to motility parameters. The aim of this study was to compare esophageal clearance determined by HRiM and TBE in patients with achalasia treated by POEM.

Eligibility Criteria

Inclusion Criteria: * The patients included are all patients treated by POEM at Bordeaux University Hospital between October 2020 and September 2024. Exclusion Criteria: * Primary POEM failure, lost to follow-up, absence of completion of the ES, TBE or HRiM pre or post poem at 3 months.

Contact & Investigator

Central Contact

Arthur BERGER, MD

✉ arthur.berger@chu-bordeaux.fr

📞 +33557656439

Principal Investigator

Arthur BERGER, MD

PRINCIPAL INVESTIGATOR

University Hospital, Bordeaux

Frequently Asked Questions

Who can join the NCT06230536 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Esophageal Achalasia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06230536 currently recruiting?

Yes, NCT06230536 is actively recruiting participants. Contact the research team at arthur.berger@chu-bordeaux.fr for enrollment information.

Where is the NCT06230536 trial being conducted?

This trial is being conducted at Pessac, France.

Who is sponsoring the NCT06230536 clinical trial?

NCT06230536 is sponsored by University Hospital, Bordeaux. The principal investigator is Arthur BERGER, MD at University Hospital, Bordeaux. The trial plans to enroll 104 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology